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Abstract
Background: Chronic hepatitis B virus (HBV) infection affects up to 7 % of the European population. Specific HBV
genotypes are associated with rapid progression to end-stage liver disease and sub-optimal interferon treatment
responses. Although the geographic distribution of HBV genotypes differs between regions, it has not been studied
in Switzerland, which lies at the crossroads of Europe.
Methods: In a retrospective analysis of 465 HBV samples collected between 2002 and 2013, we evaluated the HBV
genotype distribution and phylogenetic determinants, as well as the prevalence of serological evidence of hepatitis
delta, hepatitis C and HIV infections in Switzerland. Baseline characteristics of patients were compared across their
region of origin using Fisher’s exact test and ANOVA, and risk factors for HBeAg positivity were assessed using
logistic regression.
Results: The Swiss native population represented 15.7 % of HBV-infected patients living in Switzerland. In the
overall population, genotype D was most prevalent (58.3 %), whereas genotype A (58.9 %) was the predominant
genotype among the Swiss native population. The prevalence of patients with anti-HDV antibodies was 4.4 %.
Patients of Swiss origin were most likely to be HBeAg-positive (38.1 %). HBV genotypes of patients living in
Switzerland but sharing the same original region of origin were consistent with their place of birth.
Conclusions: The molecular epidemiology of HBV infection in Switzerland is driven by migration patterns and not
by the genotype distribution of the native population. The prevalence of positive anti-HDV antibodies in our cohort
was very low.
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Background
Hepatitis B virus (HBV) infection is a global health
problem with more than 240 million people chronically
infected worldwide and 15 million of them co-infected
with Hepatitis D virus (HDV) [1, 2]. Chronic HBV infec-
tion is an important cause of liver-related complications
including cirrhosis, hepatic failure and hepatocellular
carcinoma [3]. Based on the diversity in the complete HBV
genomic sequence, 10 HBV genotypes, A to J, and numer-
ous sub-genotypes have been described to date [4, 5].
Specific HBV genotypes have an impact on the clinical
course of disease: for instance, genotype C infection is
associated with more severe liver damage and faster pro-
gression to hepatocellular carcinoma in comparison to
genotype B [6]. Furthermore, several studies showed that
the different genotypes may vary in their ability to in-
duce chronic hepatitis and in their treatment response
to interferon [6]. Of note, HBeAg positive individuals in-
fected with the two most prevalent European genotypes,
A and D, show a different response to interferon: Geno-
type A infected individuals are more likely to have a
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sustained response to interferon treatment compared to
those with genotype D [6, 7].
The geographic distribution of HBV genotypes is well
characterized. In Europe the genotypes A (Northern-
and Eastern Europe) and D (Mediterranean basin) are
predominant, whereas genotypes B and C are most preva-
lent in Asia, and A, and E in sub-Saharan Africa [4, 8].
We hypothesized that Switzerland, which is located in the
heart of Europe, could be the geographical transition zone
between the regions where genotype D and A are predom-
inant. The prevalence of Hepatitis B surface antigen
(HBsAg) carriers in the Swiss general population is esti-
mated to be 0.3 % [9], but the HBV genotype distribution
and the proportion of patients co-infected with HDV is
unknown. In this study we assessed the HBV genotype
distribution of patients living in Switzerland by analyzing
samples of a large reference laboratory in Switzerland and
evaluated the association between genotypes and clinical,
as well as virological characteristics, including HBeAg-
positivity and serological evidence of HDV infection.
Methods
Patients
All HBV-infected Swiss residents who had HBV geno-
typing as part of their regular medical care performed in
our reference laboratory between October 2002 and
October 2013 were included in our retrospective study.
A medical chart review was conducted to collect detailed
information on the most important demographic and
clinical characteristics. Demographic characteristics in-
cluded age, sex, and region of origin. The region of ori-
gin was coded according to the patient’s nationality. In
individuals who immigrated to Switzerland and were
naturalized, the region of birth was considered. The
study was approved by the local ethics committee of the
University of Bern. Patient records were de-identified
prior to analysis. In accordance with Swiss law and the
Declaration of Helsinki no written informed consent was
obtained for this retrospective study.
HBV genotyping
From 2002 to 2009 the HBV genotype was determined
using the INNO-LiPA HBV Genotyping assay (Innoge-
netics N.V., Ghent, Belgium) according to the manufac-
turer’s protocol. From 2010 to 2013 HBV genotyping
was performed by direct sequencing using primers pub-
lished by Mallory et al. and Schildgen et al. [10, 11]. For
both methods (INNO-LiPA HBV Genotyping assay and
direct sequencing) viral DNA was extracted from the pa-
tient’s serum or plasma using NucliSENS easyMAG
(bioMérieux, Paris, France) according to the manufac-
turer’s protocol. If genotyping was performed by direct
sequencing, a fragment of 941 nucleotides of the viral
polymerase/HBsAg was amplified in a primary PCR
(pPCR) using the previously described primers HBV_1F
and HBV_4R by Mallory et al. [10]. If needed, a nested
PCR (nPCR) was performed using the primers
TGGATGTGTCTGCGGC (sense primer) and CKTTGA
CADACTTTCCAATCAATAG (antisense primer) pub-
lished by Schildgen et al. yielding a PCR product of 622
nucleotides [11].
All PCR products were analyzed by electrophoresis in
a 1 % agar gel and then purified using QIAquick PCR
Purification Kit (QIAGEN GMBH, Hilden, Germany) ac-
cording to the manufacturer’s protocol. The purified
amplicons were subjected to bidirectional Sanger se-
quencing using the previously described primer HBV_1F
and the antisense primer published by Schildgen et al.
[10, 11] for pPCR products and the primers published
by Schildgen et al. [11] for nPCR products yielding a se-
quencing product of 815 nucleotides and 622 nucleo-
tides respectively. Cycle sequencing was performed
according to Platt et al. [12]. After purification of the
cycle sequencing products by the QIAGEN DyeEx 2.0
Spin Kit (QIAGEN GMBH, Hilden, Germany) the elec-
tropherographs were acquired on a genetic analyzer AB-
3130 (Life Technologies Europe BV, Nieuwerkerk,
Netherlands) and then processed using SeqMan (DNAS-
TAR Inc., Madison, WI, USA). For in silico sequence
analysis and genotype determination the open access in-
terpretation tool geno2pheno was used provided by
Genafor at http://www.genafor.org/hbv/hbvpredict.php
described by Beggel et al. [13]. By performing direct se-
quencing combined with in silico analysis using geno2-
pheno additionally to the genotype the subgenotype
could be determined while by the INNO-LiPA assay the
genotype only was identified.
Serologic analysis
If performed in our laboratory, samples tested before April
2009 were analyzed by Abbott AxSYM (Abbott Laborator-
ies, Chicago, USA) for Anti-HBe, Anti-HCV and the HIV
status. HBeAg was tested using VIDAS (bioMérieux, Paris,
France). After April 2009 these serological parameters
were tested using ARCHITECT i2000sr (Abbott Labora-
tories, Chicago, USA). Anti-HDV was tested with ETI-
AB-DELTAK-2 (DiaSorin, Saluggia, Italy). All tests were
performed according to the manufacturer’s instruction. If
no HBeAg test, HIV, HCV or HDV serology was carried
out in our institution, we reviewed the charts to identify
analyses which were performed elsewhere.
Phylogenetic analysis
The phylogenetic analysis was performed using the Phy-
logeny.fr platform [14] with a set of 136 sequences (all
samples from 2010 to 2013) from our study of HBV in-
fected patients in Swiss residents [GenBank accession
numbers KM524121 to KM524256] and compared to 15
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reference strains from GenBank representing all geno-
types from A to G. The sequences analysed were all re-
stricted to the same 413 nucleotide stretch of the viral
polymerase containing no gaps, deletions or insertions.
The alignment was constructed using clustalW2 software
provided by the European Bioinformatic Institute at
http://www.ebi.ac.uk/Tools/msa/clustalw2/. The phylo-
genetic tree was calculated by an improved neighbour-
joining method implemented in the BioNJ program [15]
as part of the Phylogeny.fr platform. Bootstrap analysis
was carried out 1000 times for reliability confirmation of
the resulting structure. The phylogenetic tree was rooted
for non-D genotypes.
Statistical analysis
In order to analyze the genotype distribution among pa-
tients living in Switzerland with different migration back-
ground, we classified all patients into one of five “regions
of origin”: Switzerland, Europe/Mediterranean, sub-Sahara
Africa, Asia and unknown/other. The distribution of re-
gions of origin of our study population was compared
with estimates from the general population living in
Switzerland, obtained from the federal office of statistics
[16]. Baseline characteristics of patients were compared
across their original region of origin using Fisher’s exact
test and ANOVA for categorical and continuous variables,
respectively. The genotype distribution according to re-
gion of origin was described using proportional bar charts.
Risk factors for HBeAg-positivity were assessed using
logistic regression. The following explanatory variables
were included in univariable models: sex, age, region of
origin, HBV genotype, HCV-coinfection, HIV-coinfection
and serological evidence of HDV-infection. Variables sig-
nificantly associated with the outcome variable (p < 0.05)
were included in a multivariable regression model. Multiple
imputation was used to impute missing HIV and HCV
measurements at baseline, with analyses run on each of 20
datasets and results combined with Rubin’s rules [17]. In a
sensitivity analysis, the results of multivariable analyses
from the model using multiple imputation were compared
to those obtained from complete-case analyses. All analyses
were performed using Stata software version 12.0 (College
Station, Texas, USA).
Results
Baseline characteristics
Between October 2002 and October 2013, the samples
of 465 patients living in Switzerland were analyzed. The
patients originated from 57 different countries and al-
most two-thirds of them were men (63.4 %, Table 1).
The median age was 37 years (interquartile range (IQR)
29–47 years). Native Swiss individuals represented
15.7 % of the study population, whereas 38 % of patients
were from countries in Europe and the Mediterranean
basin, 20 % were of Asian and 9 % of sub-Saharan African
origin (Fig. 1). This was in strong contrast with the general
population of Switzerland, where Swiss natives repre-
sented over 80 % of the total number of people [16]. Of
note 97.2 % of the Europe and Mediterranean group pa-
tients originated from Mediterranean countries (Fig. 1).
HBV genotype distribution
Seven single genotypes could be identified, whereas only
one patient had a mixed genotype infection (AG). The
genotypes D (58.3 %) and A (15.9 %) predominated in
our study population. Among the less prevalent geno-
types, C was found in 8.8 % of cases, B in 8.0 % and E in
6.9 %. The HBV genotype distribution varied widely
across the regions of origin (Fig. 2). The native Swiss
population was mainly infected with genotypes A
(58.9 %) and D (31.5 %). Patients originating from other
European countries and the Mediterranean basin but living
in Switzerland were almost exclusively infected with geno-
type D (96.6 %). Patients originally coming from sub-
Saharan Africa were most commonly infected with geno-
types E (66.7 %) and A (28.6 %), whereas genotypes C
(34.4 %), B (33.3 %) and D (28.1 %) were most prevalent in
those of Asian origin. Importantly, the distribution of HBV
genotypes in the group of patients with unknown region of
origin was similar to the overall population (Table 1).
HDV and other co-infections
Hepatitis D serology was available for 72.7 % (338/465)
of the study population (Table 1). Anti-HDV antibodies
were detected in 4.4 % of the serum samples. Patients
originating from sub-Saharan Africa were most likely to
be anti-HDV positive (16.2 %), whereas in the Asian
group anti-HDV antibodies were least likely to be de-
tected (1.3 %). HCV serology was available for 72.5 %
(337/465) of the patients and was positive in 2.4 % of
them. The prevalence of HBV/HCV co-infection was very
low among the sub-Saharan African and the Europe and
Mediterranean groups (0 % and 0.7 %, respectively) but
higher in the Swiss group (5.2 %). Only 49.9 % (232/465)
of patients had an HIV test result available. Overall, HIV-
HBV co-infection was found in 6.5 % (15/232) of the pa-
tients and the highest prevalence was observed in patients
of sub-Saharan African origin (18.9 %).
HBeAg positivity
Data on HBeAg status was available for 84.1 % (391/465)
of the patients, of which 29.4 % were HBeAg positive.
Whereas native Swiss individuals were most likely to have
a positive HBeAg (38.1 %), its prevalence was lowest in
the European and Mediterranean group (17.4 %). In multi-
variable analysis, older age was associated with a lower
probability of being HBeAg positive (Odds ratio 0.98,
95 % confidence interval 0.96-0.99). In addition, patients
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of European and Mediterranean origin were less likely to
be HBeAg-positive compared to those of Swiss origin
(Table 2). There were no statistically significant associa-
tions between HBV genotype or HIV-coinfection and
HBeAg positivity. Of note, the estimates obtained from
the adjusted complete-case analysis were similar to our
main results (Additional file 1).
Phylogenetics
The phylogenetic tree of the partial HBV polymerase
gene of our study population is shown in Fig. 3. HBV ge-
notypes D and A were of special interest because they
are the predominant genotypes in Europe. The cluster
infected with sub-genotype D1 mainly consisted of
patients originating from Turkey (belonging to the
European and Mediterranean group). Among twenty-
two patients of Turkish nationality, twenty were infected
Fig. 1 Regions of origin of HBV infected individuals in comparison
to the general population in Switzerland. Left bar: distribution of
regions of origin of the study population. Right bar: regions of origin
of the overall population of Switzerland. *Data from Swiss Federal
office for statistics [16]
Table 1 Characteristics by regions of origin
N All Switzerland Europe and Mediterranean Sub-Saharan Africa Asia Unknown and other p -value
n(%) n(%) n(%) n(%) n(%)
Total 465 73 (15.7 %) 177 (38.1 %) 42 (9.0 %) 96 (20.6 %) 77 (16.6 %)
Sex 0.02
Female 170 36.6 % 19 (35.2 %) 63 (35.6 %) 11 (26.2 %) 46 (47.9 %) 31 (40.3 %)
Male 295 63.4 % 54 (64.8 %) 114 (64.4 %) 31 (73.8 %) 50 (52.1 %) 46 (59.7 %)
Median age 465 37 45 37 30 37 37 <0.001
(IQR 29–47) (IQR 35–55) (IQR 29–46) (IQR 26–36) (IQR 29–44) (IQR 28–46)
Genotype 465 <0.001
A 74 15.9 % 43 (58.9 %) 6 (3.4 %) 12 (28.6 %) 4 (4.2 %) 9 (11.7 %)
AG 1 0.2 % 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (1.3 %)
B 37 8.0 % 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 32 (33.3 %) 5 (6.5 %)
C 41 8.8 % 5 (6.9 %) 0 (0.0 %) 0 (0.0 %) 33 (34.4 %) 3 (3.9 %)
D 271 58.3 % 23 (31.5 %) 170 (96.1 %) 2 (4.8 %) 27 (28.1 %) 49 (63.6 %)
E 32 6.9 % 0 (0.0 %) 0 (0.0 %) 28 (66.7 %) 0 (0.0 %) 4 (5.2 %)
F 5 1.1 % 2 (2.7 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 3 (3.9 %)
G 4 0.9 % 0 (0.0 %) 1 (0.6 %) 0 (0.0 %) 0 (0.0 %) 3 (3.9 %)
HBe Antigen Status 391 63 161 39 89 39 <0.001
positive 115 29.4 % 24 (38.1 %) 28 (17.4 %) 11 (28.2 %) 39 (33.7 %) 13 (33.3 %)
negative 276 70.6 % 39 (61.9 %) 133 (82.6 %) 28 (71.8 %) 50 (66.3 %) 26 (66.7 %)
HDV Status 338 53 141 37 77 30 0.03
HDV positive 15 4.4 % 2 (3.8 %) 5 (3.6 %) 6 (16.2 %) 1 (1.3 %) 1 (3.3 %)
HDV negative 323 95.6 % 51 (96.2 %) 136 (96.4 %) 31 (83.8 %) 76 (98.7 %) 29 (96.7 %)
HCV Status 337 55 140 37 78 27 0.06
HCV positive 8 2.4 % 3 (5.2 %) 1 (0.7 %) 0 (0.0 %) 2 (2.6 %) 2 (7.4 %)
HCV negative 329 97.6 % 52 (94.8 %) 139 (99.3 %) 37 (100 %) 76 (97.4 %) 25 (92.6 %)
HIV Status 232 31 90 37 55 19 <0.001
HIV positive 15 6.5 % 5 (16.1 %) 0 (0 %) 7 (18.9 %) 1 (1.8 %) 2 (10.5 %)
HIV negative 217 93.5 % 26 (93.9 %) 90 (100 %) 30 (81.8 %) 54 (98.2 %) 17 (89.5 %)
HDV Hepatitis D virus, HCV Hepatitis C virus, HBeAg Hepatitis B envelope antigen, HIV Human immunodeficieny virus, IQR Interquartile range
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with this sub-genotype. With the exception of two sam-
ples belonging to patients of unknown origin, the D2
cluster consisted exclusively of patients from the Balkan
region (European and Mediterranean group). Of seven
patients from the Swiss group carrying HBV genotype D,
five were infected with the sub-genotype D3. The D4
cluster consisted of patients originating from China
(Asian group) and from the Mediterranean basin. Fi-
nally, the A1 cluster consisted predominantly of patients
originating from sub-Saharan Africa, whereas the A2
cluster was mainly represented by Swiss native patients.
Discussion
In this large and representative sample of HBV-infected
patients living in Switzerland, we showed that HBV-
related epidemiological and virological determinants were
driven by migration patterns. The largest group of individ-
uals originally originated from the Mediterranean basin
and was predominantly infected with HBV genotype D.
We found substantial differences in demographic and
virological characteristics between groups of individuals of
different regions of origin, including HBV genotype distri-
bution and proportion of viral co-infections. The Swiss
native population showed the typical genotype distribution
of Northern European countries where patients are most
commonly infected with genotype A. Serological evidence
of HDV infection was surprisingly low, except for patients
of sub-Saharan African origin, of which 16 % were anti-
HDV positive. In line with other European studies, older
patients were least likely to have a positive HBeAg.
Fig. 2 Hepatitis B virus genotypes by region of origin. The bars represent the frequency of the different HBV genotypes by regions of origin
Table 2 Risk factors for HBeAg positivity
N Odds ratio univariable analysis p-value Odds ratio multivariable analysis p-value
Sex 391
Female 170 1 0.61
Male 221 1.12 (0.71–1.78)
Age 391 0.98 (0.97–0.99) 0.04 0.98 (0.96–0.99) 0.02
Genotype 391
A 67 1 1
B 31 0.96 (0.38–2.45) 0.93 0.79 (0.23–2.65) 0.70
C 36 2.63 (1.14–6.07) 0.02 1.99 (0.67–5.91) 0.22
D 222 0.77 (0.42–1.42) 0.41 1.57 (0.70–3.54) 0.28
E 28 0.94 (0.36–2.49) 0.90 1.37 (0.35–5.35) 0.64
F 7 3.13 (0.64–15.30) 0.16 4.11 (0.73–23.10) 0.11
Region of origin 391
Switzerland 63 1 1
Europe and Mediterranean 161 0.34 (0.18–0.66) 0.01 0.24 (0.10–0.57) 0.01
Sub-Saharan Africa 39 0.64 (0.27–1.51) 0.31 0.42 (0.11–1.53) 0.19
Asia 89 1.27 (0.66–2.45) 0.48 1.03 (0.41–2.58) 0.94
Unknown and Other 39 0.81 (0.35–1.88) 0.63 0.53 (0.20–1.40) 0.20
HIV Status 228 0.03 0.11
HIV positive 15 4.51 (1.45–14.01) 2.53 (0.82–7.84)
95 % Conf. Interval in brackets; HIV Human Immunodeficiency virus
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Fig. 3 (See legend on next page.)
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Although only 23.8 % of the population in Switzerland
consists of immigrants [16], patients originating from
the Mediterranean basin, sub-Saharan Africa as well as
Asia represented over 84 % of our study population. The
overall HBV genotype distribution showed a typical
Mediterranean pattern with a predominance of genotype
D mainly due to the large proportion of patients from
Portugal, Italy, Turkey and the Balkan region. The geno-
type distribution among the Swiss native population dif-
fered considerably from that of the overall study
population and was comparable to patterns described
for Germany, Belgium, Poland, the Czech Republic and
Scandinavia [8]. As shown previously for Iceland, our
study underlines the role played by migration patterns in
shaping the epidemiological and virological landscape of
HBV infection in countries with a low HBV prevalence
in the domestic population [18]. Considering the strong
link between HBV genotype and the natural history of
disease as well as the better response to interferon treat-
ment in genotype A compared to genotype D infected
patients, a careful evaluation of the region of origin as
well as the determination of HBV genotype for all pa-
tients might be warranted in countries like Switzerland.
Phylogenetic analyses showed that the Swiss native
population was mainly infected with the sub-genotypes
A2 and D3. Thus, Switzerland seems to be a geograph-
ical transition zone for HBV infection, between Italy,
where the sub-genotype D3, is most prevalent [19] and
northern European countries, where the sub-genotype
A2 predominates [8]. The phylogenetic analyses of geno-
type D strains were particularly informative: Patients of
Turkish origin were predominantly infected with the
genotype D1, in line with a recent report on HBV infec-
tion in Turkey [20]; Furthermore, in our study, HBV D2
virus seemed to circulate primarily among patients who
immigrated from the Balkan region which is consistent
with the findings of Zehender et al. in Albania [21].
Interestingly four patients of Asian origin (two Tibetans,
one Chinese and one of unknown origin) have clustered
in subgenotype D4. This is unusual for HBV strains of
this region and was not described before except for a re-
port of C/D4 recombinants from Tibet where 96.8 % of
the HBV strains analyzed showed a C/D4 recombinant
pattern [22]. Due to the short fragment analyzed in our
study one cannot exclude that the four samples would
belong to the recombinant C/D4 genotype. Taken to-
gether, these results show that several homogeneous
clusters of HBV-sub-genotypes have established in
Switzerland, owing to migration patterns, and that the
Swiss native HBV-infected population has a genotype
distribution consistent with its geographical situation.
Hepatitis D co-infection is clinically important because
it causes more severe liver disease and accelerated pro-
gression to cirrhosis leading to higher rates of hepatic
decompensation and mortality compared to HBV mono-
infection [23]. The prevalence of HBV/HDV co-infection
varies widely across European countries, ranging from
2 % in Great Britain to 46 % in eastern Turkey [24, 25].
The overall decreasing prevalence of HDV-co-infection
observed in recent years has been attributed to the de-
cline of chronic HBV carriers following the introduction
of vaccination programs [2]. In Switzerland, we found
4.4 % of the chronic HBV-infected patients to be anti-
HDV positive, which was slightly lower than the 5.9 %
estimated in a recent survey completed by physicians treat-
ing HBV-infected patients in 2008 [26]. In contrast to the
low overall rate of patients with positive anti-HDV anti-
bodies in our study population, 16 % of the patients from
sub-Saharan Africa in our study were anti-HDV positive, in
line with reported estimates from West Africa [27].
Seventy percent of our study population was HBeAg-
negative. The increasing predominance of HBeAg-negative
HBV infections was highlighted in a recent French study
[28] and a report from Italy showed that the proportion of
HBeAg-negative infections increased from 41 % between
1975 and 1985 to 90 % in the 1990′s [29]. In line with
other European studies, older patients and those originat-
ing from the Mediterranean basin were less likely to have a
positive HBeAg [30]. A possible explanation for the signifi-
cantly lower rate of HBeAg-positive patients among the
Europe and Mediterranean group compared to the Swiss
group in our study could be the already previously de-
scribed short duration of the immune reactive HBeAg
positive phase in the Mediterranean population with subse-
quent HBeAg loss in combination with the high prevalence
of precore mutations in this population [30].
This is one of the largest studies evaluating epidemio-
logical and virological patterns of HBV infection in a
low prevalence country and the first study assessing the
HBV genotype distribution as well as the HDV seropreva-
lence of HBV-infected patients in Switzerland. The detailed
virological and phylogenetic analyses allowed us to describe
the main determinants of HBV infection in Switzerland, a
country with a highly diverse HBV landscape due to its
(See figure on previous page.)
Fig. 3 Dendogram of Hepatitis B virus in Swiss residents. Region of origin is illustrated by different colours: Swiss (blue), Asian (purple), European/
Mediterranean (EuMed, red), sub Saharan African (ssAfr, green), unknown or other (Unkn/Oth, turquois), reference sequences (REFsequ, black).
Each sample is labelled with Genotype_GenBank accession number_region of origin/country code. The country codes are provided in the
supplemental material (Additional file 1: Table S2). *The bar length indicates the distance of a 1 nucleotide (nt) polymorphism. The number in the
tree indicates the bootstrap reliability
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geographical situation as well as its migration patterns.
Our study had several limitations. The individual patient
data were collected retrospectively, resulting in partially in-
complete information on several key variables such as
HIV-coinfection. This is of importance as the epidemio-
logical and clinical determinants of HBV infection are
linked to the presence of HIV-coinfection [31]. It also un-
derlines the importance of conducting prospective, large
cohort studies dedicated to the study of HBV infection. In
addition we did not know the region of origin of 70 pa-
tients, representing 16.6 % of the study population. How-
ever, as the genotype distribution in this group was similar
to that of the overall study population, this should not have
had a major impact on the overall results. Instead of using
full genome phylogenetic analyses (gold standard) to deter-
mine HBV sub-genotypes, we analyzed a fragment of the
polymerase/HBsAg using the geno2pheno tool. However,
to verify the accuracy of our phylogenetic analysis we
inserted reference sequences for every HBV subgenotype.
Finally, only serological analyses for HDV status were avail-
able, therefore the proportion of patients with replicating
HDV infection in our cohort was unknown.
Conclusions
We showed that the molecular epidemiology of HBV in-
fection in low prevalence countries like Switzerland is
mainly driven by migration and not by the genotype distri-
bution of the native population. The predominance of
genotype D in the overall population can be explained by
immigration of patients infected with HBV sub-genotypes
D1 and D2 from Turkey and the Balkan region, respect-
ively. The HBV genotype distribution in native Swiss indi-
viduals mainly included genotypes A2 and D3, which are
most prevalent in neighboring countries. In light of these
results and considering the impact of HBV genotypes on
the course of disease and treatment response, the region
of origin and, ideally genotypes, should be assessed in all
patients in order to improve management. To address the
most important research questions regarding the impact
of HBV genotypes on clinical outcomes and treatment re-
sponse, large, prospective cohorts of HBV-infected pa-
tients need to be established.
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Abbreviations
HBV: Hepatitis B virus; HDV: Hepatitis D virus; HBeAg: Hepatitis B envelope
antigen; HBsAg: Hepatitis B surface antigen; DNA: Desoxyribonucleic acid;
PCR: Polymerase chain reaction; HIV: Human immunodeficiency virus;
HCV: Hepatitis C virus; ANOVA: Analysis of variance; NCBI: National center for
biotechnology information.
Competing interests
Cédric Hirzel: has no competing interests
Gilles Wandeler: has no competing interests
Marta Owczarek: has no competing interests
Meri Gorgievski-Hrisoho: has no competing interests
Jean-Francois Dufour: has no competing interests
Nasser Semmo: has no competing interests
Samuel Zürcher: has no competing interests
Authors’ contributions
CH: study concept and design, acquisition of data, interpretation of data,
drafting of manuscript. GW: statistical analysis, drafting of manuscript. MO:
technical support for phylogenetic analysis. MG-H: critical revision of the
manuscript for important intellectual content. J-FD: critical revision of the
manuscript for important intellectual content. NS: critical revision of the
manuscript for important intellectual content. SZ: study concept and design,
performance of molecular biological analysis. All authors read and approved
the final version of the manuscript.
Authors’ information
Nasser Semmo and Samuel Zürcher are Joint Senior Authors transferred.
Acknowledgements
This study was enabled by providing protected research time to Cédric
Hirzel during working hours by the Department of Infectious Diseases, Bern
University Hospital and University of Bern. Gilles Wandeler was supported by
an Ambizione-PROSPER fellowship from the Swiss National Science Foundation
(PZ00P3_154730).
Author details
1Department of Infectious Diseases, Bern University Hospital and University
of Bern, Bern, Switzerland. 2Hepatology Unit, Department of Visceral Surgery
and Medicine University Hospital Bern, Bern, Switzerland. 3Institute for
Infectious Diseases, University of Bern, Bern, Switzerland.
Received: 13 March 2015 Accepted: 19 October 2015
References
1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis
B virus infection: new estimates of age-specific HBsAg seroprevalence and
endemicity. Vaccine. 2012;30(12):2212–9. doi:10.1016/j.vaccine.2011.12.116.
2. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet.
2011;378(9785):73–85. doi:10.1016/S0140-6736(10)61931-9.
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:
special emphasis on disease progression and prognostic factors. J Hepatol.
2008;48(2):335–52. doi:10.1016/j.jhep.2007.11.011.
4. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis
B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33(2):97–
102. doi:10.1055/s-0033-1345716.
5. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK,
et al. Genetic diversity of hepatitis B virus strains derived worldwide:
genotypes, subgenotypes, and HBsAg subtypes. Intervirology.
2004;47(6):289–309. doi:10.1159/000080872.
6. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral
treatment influenced by hepatitis B virus genotype? J Hepatol.
2010;52(3):441–9. doi:10.1016/j.jhep.2009.12.014.
7. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al.
Factors that predict response of patients with hepatitis B e antigen-positive
chronic hepatitis B to peginterferon-alfa. Gastroenterology.
2009;137(6):2002–9. doi:10.1053/j.gastro.2009.08.061.
8. Schaefer S. Hepatitis B, virus genotypes in Europe. Hepatol Res.
2007;37(s1):S20–6. doi:10.1111/j.1872-034X.2007.00099.x.
9. Bart PAFP. Seroprävalenz von Hepatitis B bei 9000 Gebärenden in der
Schweiz von 1990 bis 1991. BAG Bull. 1996;8:3–6.
10. Mallory MA, Page SR, Hillyard DR. Development and validation of a hepatitis
B virus DNA sequencing assay for assessment of antiviral resistance, viral
genotype and surface antigen mutation status. J Virol Methods.
2011;177(1):31–7. doi:10.1016/j.jviromet.2011.06.009.
Hirzel et al. BMC Infectious Diseases  (2015) 15:483 Page 8 of 9
11. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant
of hepatitis B virus with primary resistance to adefovir. N Engl J Med.
2006;354(17):1807–12. doi:10.1056/NEJMoa051214.
12. Platt AR, Woodhall RW, George Jr AL. Improved DNA sequencing quality
and efficiency using an optimized fast cycle sequencing protocol.
Biotechniques. 2007;43(1):58. 60, 2.
13. Beggel B, Neumann-Fraune M, Doring M, Lawyer G, Kaiser R, Verheyen J, et
al. Genotyping hepatitis B virus dual infections using population-based
sequence data. J Gen Virol. 2012;93(Pt 9):1899–907. doi:10.1099/vir.0.043042-0.
14. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, et al.
Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic
Acids Res. 2008;36(Web Server issue):W465–9. doi:10.1093/nar/gkn180.
15. Gascuel O. BIONJ: an improved version of the NJ algorithm based on a
simple model of sequence data. Mol Biol Evol. 1997;14(7):685–95.
16. http://www.bfs.admin.ch [Internet]. Neuchatel: Federal office for statistics.
[updated 2014 January 24; cited 2014 June 17]. Available from: http://
www.bfs.admin.ch/bfs/portal/de/index/themen/01/02/blank/key/alter/
nach_staatsangehoerigkeit.html. Accessed 17 June 2014.
17. Rubin DB. Multipe imputation for nonresponse in surveys. New York: John
Wiley & Sons; 1987.
18. Bjornsdottir TB, Stanzeit B, Sallberg M, Love A, Hultgren C. Changing
prevalence of hepatitis B virus genotypes in Iceland. J Med Virol.
2005;77(4):481–5. doi:10.1002/jmv.20480.
19. Zehender G, Ebranati E, Gabanelli E, Shkjezi R, Lai A, Sorrentino C, et al.
Spatial and temporal dynamics of hepatitis B virus D genotype in Europe
and the Mediterranean Basin. PLoS One. 2012;7(5):e37198. doi:10.1371/
journal.pone.0037198.
20. Bozdayi G, Turkyilmaz AR, Idilman R, Karatayli E, Rota S, Yurdaydin C, et al.
Complete genome sequence and phylogenetic analysis of hepatitis B virus
isolated from Turkish patients with chronic HBV infection. J Med Virol.
2005;76(4):476–81. doi:10.1002/jmv.20386.
21. Zehender G, Shkjezi R, Ebranati E, Gabanelli E, Abazaj Z, Tanzi E, et al.
Reconstruction of the epidemic history of hepatitis B virus genotype D in
Albania. Infect Genet Evol. 2012;12(2):291–8. doi:10.1016/
j.meegid.2011.11.009.
22. Shen L, Yin W, Zheng H, Cui F, Zhang S, Wang F, et al. Molecular
epidemiological study of hepatitis B virus genotypes in Southwest, China. J
Med Virol. 2014;86(8):1307–13. doi:10.1002/jmv.23965.
23. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al.
Influence of hepatitis delta virus infection on morbidity and mortality in
compensated cirrhosis type B. The European concerted action on viral
hepatitis (Eurohep). Gut. 2000;46(3):420–6.
24. William Tong CY, Asher R, Toby M, Ngui SL, Tettmar K, Ijaz S, et al. A re-
assessment of the epidemiology and patient characteristics of hepatitis D
virus infection in inner city London. J Infect. 2013;66(6):521–7. doi:10.1016/
j.jinf.2013.02.006.
25. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M.
Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B
patients in eastern Turkey: still a serious problem to consider. J Viral
Hepatitis. 2011;18(7):518–24. doi:10.1111/j.1365-2893.2010.01329.x.
26. Genne D, Rossi I. Hepatitis delta in Switzerland: a silent epidemic. Swiss Med
Wkly. 2011;141:w13176. doi:10.4414/smw.2011.13176.
27. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al.
Characterization of hepatitis delta virus in sub-Saharan Africa. J Clin
Microbiol. 2014;52(5):1629–36. doi:10.1128/JCM.02297-13.
28. Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, et al.
Characteristics of patients with chronic hepatitis B in France: predominant
frequency of HBe antigen negative cases. J Hepatol. 2006;45(3):355–60.
doi:10.1016/j.jhep.2006.03.007.
29. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini
T, et al. Epidemiological and clinical burden of chronic hepatitis B virus/
hepatitis C virus infection. A multicenter Italian study. J Hepatol.
2003;39(6):1036–41.
30. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean
and African countries. J Hepatol. 2011;55(1):183–91. doi:10.1016/
j.jhep.2010.12.030.
31. Martin-Carbonero L, Poveda E. Hepatitis B virus and HIV infection. Semin
Liver Dis. 2012;32(2):114–9. doi:10.1055/s-0032-1316466.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hirzel et al. BMC Infectious Diseases  (2015) 15:483 Page 9 of 9
